Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADRES: Axitinib in Renal Cell Carcinoma
NCT03438708Phase 2Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Mar 2018
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by University of California, San Diego. Started Mar 2018; status: active, not recruiting.
02
Drugs
axitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03438708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03438708.